Barclays PLC Has $1.36 Million Stock Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Barclays PLC boosted its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 9,643.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 31,471 shares of the company’s stock after buying an additional 31,148 shares during the period. Barclays PLC’s holdings in Establishment Labs were worth $1,362,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Hood River Capital Management LLC purchased a new stake in shares of Establishment Labs in the 2nd quarter valued at approximately $43,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Establishment Labs in the 3rd quarter valued at about $127,000. Nkcfo LLC purchased a new position in Establishment Labs during the second quarter valued at approximately $227,000. Black Swift Group LLC acquired a new position in Establishment Labs in the 3rd quarter valued at approximately $312,000. Finally, Verition Fund Management LLC raised its stake in shares of Establishment Labs by 22.8% during the 3rd quarter. Verition Fund Management LLC now owns 9,400 shares of the company’s stock worth $407,000 after purchasing an additional 1,746 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Stock Down 0.6 %

Shares of ESTA stock opened at $45.94 on Friday. Establishment Labs Holdings Inc. has a one year low of $24.42 and a one year high of $60.12. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29. The stock has a fifty day moving average price of $43.94 and a 200 day moving average price of $43.61. The stock has a market cap of $1.29 billion, a P/E ratio of -17.81 and a beta of 1.16.

Wall Street Analyst Weigh In

ESTA has been the subject of a number of recent research reports. BTIG Research upped their price objective on shares of Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Stephens upgraded shares of Establishment Labs to a “strong-buy” rating in a report on Monday, December 2nd. Finally, Citigroup raised their price objective on shares of Establishment Labs from $45.00 to $50.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Establishment Labs presently has an average rating of “Buy” and an average target price of $60.60.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.